Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

Conditions:Cancer, Blood Cancer, Blood Cancer, Blood Cancer, Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Age Range:Any - 25
Start Date:November 2011
End Date:June 2021
Contact:Mitchell S Cairo, MD

Use our guide to learn which trials are right for you!

A Pilot Study of Gemtuzumab Ozogamicin in Combination With Busulfan and Cyclophosphamide (Immunochemotherapy) and Allogeneic Stem Cell Transplantation in Patients With High Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Targeted immune therapy with gemtuzumab ozogamicin (Mylotarg) in combination with
chemotherapy followed by allogeneic stem cell transplantation will be given to patients with
high risk acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).

Gemtuzumab ozogamicin in combination with busulfan and cyclophosphamide (immunochemotherapy)
conditioning followed by allogeneic stem cell transplantation + anti-thymocyte globulin
(unrelated donors only) in patients with high risk CD33+AML or MDS meeting eligibility

Inclusion Criteria:

- Disease Status:

- History of AML Induction/Reinduction Failure

- AML 1st Complete Remission (CR) with poor cytogenetics

- AML 2nd CR with minimal residual disease (MRD)

- AML 3rd CR

- AML in refractory relapse but ≤25% bone marrow leukemia blasts

- MDS with >6% bone marrow blasts at diagnosis

- Secondary MDS with ≤5% bone marrow myeloblasts at diagnosis

Disease Immunophenotype:

• Disease must express a minimum of >/= 10% CD33+ for patients with AML

Organ Function:

• Adequate renal function, adequate liver function, adequate cardiac function, adequate
pulmonary function Age: ≤25 years of age Donor: matched family donor, unrelated cord blood
donor, unrelated adult donor

Exclusion Criteria:

- Patients with active central nervous system (CNS) AML/MDS disease at time of
conditioning therapy

- Female patients who are pregnant

- Karnofsky <50% or Lansky <50% if 10 years or less

- Age >25 years

- Has received gemtuzumab in the previous 30 days or has not recovered from prior
gemtuzumab therapy.
We found this trial at
40 Sunshine Cottage Road
Valhalla, New York 10595
(914) 594-4000
Principal Investigator: Mitchell S Cairo, MD
Phone: 914-594-2152
New York Medical College The College was founded in 1860 by a group of New...
Valhalla, NY
Click here to add this to my saved trials